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Abstract
Osteoclasts are bone tissue macrophages critical to maintain
bone homeostasis. However, whether osteoclasts are suscep-
tible to flaviviral infections and involved in dengue virus
(DV)-induced disease pathogenesis is still unknown. In this
study, we found that osteoclasts were preferentially suscepti-
ble to DV infection and produced similar amounts of cyto-
kines and infectious virions as macrophages. Interestingly,
DV-induced cytokine secretion and nuclear translocation of
the transcription factor NFATc1 in osteoclast via the Syk-
coupled myeloid C-type lectin member 5A (CLEC5A).
Moreover, DV caused transient inflammatory reaction in bone
tissue and upregulated osteolytic activity to release C-
telopeptide of type I collagen (CTX-1) from bone tissue.
Furthermore, DV-induced osteolytic activity was attenuated
in CLEC5A-deficient mice, and administration of antagonistic
anti-CLEC5A mAb inhibited DV-activated osteolytic activity
and reduced CTX-1 serum level in vivo. This observation
suggests that osteoclasts serve as a novel target for DV, and
transient upregulation of osteolytic activity may contribute to
the clinical symptoms in dengue patients.
Key messages
& Cultured osteoclasts were susceptible to DV infection.
& Osteoclasts produced similar amounts of cytokines and
infectious virions as macrophages.
& DV induced nuclear translocation of NFATc1 in osteoclast
via CLEC5A.
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& DV caused transient inflammatory reaction in bone tissue
and upregulated osteolytic activity.
& Antagonistic anti-CLEC5A mAb inhibited DV-activated
osteolytic activity in vivo.
Keywords Osteoclasts .Denguevirus . Syk-coupledmyeloid
C-type lectinmember 5A (CLEC5A)
Introduction
Osteoclasts are multinucleated giant cells differentiated from
mononuclear macrophage/monocyte-lineage precursors.
Incubation of monocytes with M-CSF and RANK ligand
(RANKL) induces monocyte differentiation into osteoclasts
in vitro, and stimulation of osteoclast precursors with
RANKL in vivo induces cell migration onto the bone surface,
where they fuse with each other to form multinucleated giant
cells with osteolytic activity. Even though activation of oste-
oclasts contributes metabolic and inflammatory bone diseases
[1, 2], it is still unclear whether osteoclasts are susceptible to
viral infections and contribute to immunopathology and dis-
ease pathogenesis.
Dengue is one of the most important vector-borne diseases
in the world, with approximately 50–100 million cases occur-
ring annually [3]. However, neither effective vaccine nor spe-
cific treatment to alleviate clinical symptoms and reduce le-
thality is available. We have demonstrated that the spleen ty-
rosine kinase (Syk)-coupled C-type lectin 5A (CLEC5A) in-
teracts with dengue virus (DV) [4] and Japanese encephalitis
virus (JEV) [5] directly and is critical for DV-induced hemor-
rhagic shock and JEV-induced neuroinflammation. Moreover,
DV is able to activate NALP3 inflammasome via CLEC5A to
secrete IL-1β, IL-18, and other proinflammatory cytokines
from GM-CSF-induced inflammatory macrophages [6, 7].
All the evidence suggests that CLEC5A is a critical factor
for the pathogenesis of flavivirus-induced systemic inflamma-
tory reactions [8].
In addition, agonistic anti-CLEC5A mAb is able to in-
crease the RANKL-induced osteoclastogenesis in vitro [9],
thus enhancing recruitment of inflammatory macrophages
and neutrophils to promote bone erosion [10]. The potential
role of CLEC5A in the pathogenesis of human rheumatoid
arthritis (RA) is further supported by the observation that
CLEC5A-positive monocytes increase in active RA patients
[11]. All the evidence suggests that CLEC5A is not only crit-
ical for flaviviruses-mediated systemic and neuronal inflam-
mation but also involved in regulation of osteoclast activity.
It has been shown that myeloid cells (such dendritic cells
andmacrophages) are the primary targets for DVinfection and
replication [4, 12]. Osteoclasts, the tissue macrophages locat-
ed in bone tissues, are critical to maintain bone homeostasis
and bone remodeling. In addition, osteoclasts play a part in
pain due to the inflammation adjacent to bone [13], and sup-
pression of osteoclast activity is able to suppress the osteopo-
rotic pain [14]. However, whether osteoclasts are susceptible
to DV infection and are involved in the pathogenesis of DV-
induced pain sensation has not been investigated yet. To ad-
dress this question, osteoclasts derived from human mono-
cytes and STAT1-deficient mouse bone marrow were infected
with DV2 PL046 strain (DV serotype 2, clinical isolate in
Taiwan) for in vitro study, while mouse adapted strain New
Guinea C-N strain (DV serotype 2) was used to infect STAT1-
deficient mice for in vivo study, as wild-type mice are resistant
to dengue virus infection.
Here, we demonstrate that DV not only infects and repli-
cates in osteoclasts but also stimulates the secretion of inflam-
matory cytokines. Moreover, DVupregulates osteolytic activ-
ity via CLEC5A, and CLEC5A-deficient mice are resistant to
DV-induced pathological changes. Furthermore, antagonistic
anti-CLEC5A mAb inhibits DV-induced osteoclast activation
and bone erosion in vivo. Thus, DV-activated osteoclasts may
contribute significantly to the clinical symptoms in DV-
infected patients, and blockade of CLEC5A has the potential
to alleviate DV-induced immunopathology and clinical symp-
toms in dengue patients.
Material and methods
Ethic statement
Human monocytes were obtained from healthy donors at the
Taipei Blood Center of the Taiwan Blood Services
Foundation, under a protocol (AS-IRB01-14037) approved
by the IRB of the Clinical Center of the Department of
Health, Taiwan. Written informed consent was obtained from
all donors. All animal studies were performed according to the
animal study protocol approved by the Animal Experimental
Committee of National Yang-Ming University (IACUC
#981248) and in accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of
the Taiwanese Council of Agriculture. All surgeries were per-
formed under sodium pentobarbital anesthesia, and every ef-
fort was made to minimize suffering.
Reagents
Culture media/supplements were from Invitrogen GIBCO.
Chemical reagents and tartrate-resistant acid phosphatase
(TRAP) stain (catalogue no. 387–1) was from Sigma.
Macrophage-colony-stimulating factor (M-CSF) and recom-
binant TNFSF11 (soluble RANKL) for human and mouse,
DuoSet ELISA kit for TNF-α, and IL-6 were purchased from
R&D Systems. Antibody against NFATc1 (sc-7294) was from
Santa Cruz. Bone slice (DT-1BON1000-96), CrossLaps for
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Culture kit (AC-07F1), RatLaps (AC06F1), and Serum
CrossLaps (AC02F1) for CTX-1 detection were purchased
from Nordic Bioscience Diagnostics. The PE-conjugated an-
ti-CD51/61 mAb and isotype-matched control for FACS anal-
ysis were from BD Pharmingen. Anti-CLEC5A mAb was
generated as previous description [4].
Osteoclast differentiation
The CD14+ monocyte-derived osteoclasts were obtained as
described previously [15]. For mouse osteoclast differentia-
tion, bone marrow cells (5×106) were seeded on Petri dish
(10 cm in diameter) for 24 h, followed by collecting the
nonadherent cells and incubated in α-MEM medium supple-
mented with 20 ng/ml of M-CSF and 50 ng/ml of RANKL for
further 8 days. Before harvesting, cells were examined under a
microscope (Leica Ltd) to determine multinucleated feature
and were subjected to the TRAP assay and counterstained
with Hoechst/phalloidin to determine osteoclast maturation
[16].
Virus
Dengue virus (DV2-PL046) and New Guinea C-N (DV2)
strain were used for all in vitro studies and mouse infection
model, respectively, and were propagated in C6/36 mosquito
cell line. Viral titers were determined by plaque-forming as-
says using BHK-21 cells [4]. The neurovirulent Japanese en-
cephalitis virus (RP-9) and the West Nile Virus (B-956 strain,
Uganda) were used for comparison with DV in the in vitro
assay.
TRAP staining
Osteoclast formation was determined by detection of TRAP-
positive cells as vendor’s instruction (Sigma-Aldrich). Briefly,
cells were fixed for 30 s and incubated with a solution con-
taining naphthol AS-BI phosphoric acid at 37 °C for 1 h. The
naphthol AS-BI phosphoric acid hydrolyzed by TRAP
coupled immediately with fast garnet GBC to form insoluble
maroon dye deposited at sites of activity. Stained cells were
subjected to a counterstain with a hematoxylin solution.
Osteoclasts were determined as TRAP-positive, multinucleat-
ed giant cells using light microscopy. The number of TRAP-
positive cells and the number of nuclei per TRAP-positive cell
in each well were counted, and the morphological features of
osteoclasts were also photographed.
Bone resorption assay
Mature osteoclasts (2 × 104) were seeded on bone slices
(Nordic Bioscience Diagnostics) and incubated with DV
(M.O.I=5) at 37 °C in α-MEM media (50 μl/96-well) for
2 h. After removing unbound DV, cells and bone slice were
further incubated in fresh α-MEMmedia (200 μl/96-well). At
day 6 postinfection, supernatants were collected and the
amount of C-telopeptide of type I collagen (CTX-1) was de-
termined by ELISA kit (CrossLaps for Culture), while bone
slices were incubated with 10 % (v/v) ammonium to remove
osteoclast, followed by incubation with 1 % (v/v) toluidine
blue dissolved in 1 % sodium borate for 5 min to detect the
resorbed area (pit). Pit numbers of each field were derived
from the average of five images per bone slice under inverted
microscope (×200).
Inoculation of virus
Female WT, Stat1−/− , Stat−/−Clec5A−/−mice [5] in C57BL/6
background (6–8 weeks old) bread at the YMU Animal
Center were inoculated intraperitoneally with 2×105 PFUs
of DV2 (New Guinea C-N) in 100 μl of PBS, as well as
injected intracranially (i.c.) with 30 μl of PBS into the right
hemisphere of mouse brains. For in vivo blocking assay, anti-
CLEC5A mAb (clone 3D2H6) or isotype control (100 μg per
mouse) were administrated intraperitoneally (i.p.) on days 0,
2, 4, and 6 after DV infection.
Immunofluorescence staining
DV-infected osteoclasts were fixed and permeabilized.
Antibody against DV nonstructural protein NS3 (20 μg/ml)
or anti-NFATc1 (1:50) were incubated with cells at room tem-
perature for 2 h, followed by incubating with Cy3-conjugated
donkey anti-mouse IgG (Jackson ImmunoResearch), then
were probed with DyLight 488 Phalloidin (Thermo product
no. 21833) at a dilution of 1:500 for 30 min and then counter-
stained with Hoechst 33342. Cover slips were mounted and
observed using an FV-1000 laser scanning microscope.
SPECT/CTand PET/CT imaging
Each mouse was injected intravenously with a 37 MBq/
0.15 ml of 99mTc-methylene diphosphonate (MDP), and the
images were acquired at 2 h after injection by using the
Triumph® PET/SPECT/CT imaging scanner, preclinical imag-
ing subsystem CZT SPECT, and X-O microCT (TriFoil
Imaging, Inc.) for whole-body spiral tomography bone imag-
ing. Sixty-four projections (28 s per projection, ROR 4 cm,
FOV 5.28 cm) were made in a 180°, orbit and total acquisition
time was 30 min. In PET/CT image, each mouse was injected
in t r avenous ly wi th 15–20 MBq/0 .1 ml of 1 8F -
fluordeoxyglucose (FDG) and the images were acquired at
1 h after injection with the Triumph® PET/SPECT/CT imag-
ing scanner, preclinical imaging subsystem Lab4, and X-O
microCT (TriFoil Imaging, Inc.) for inflammatory detection.
Before the SPECT and PET scan, the mouse was imaged with
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CT scan to acquire anatomical information (X-ray source:
50 kV, 0.28mA; 512 projections). The SPECTand PET image
datasets were then reconstructed using the ordered-subset ex-
pectation maximization algorithm with standard-mode param-
eters and 2D maximum likelihood expectation maximization
(MLEM) algorithm, respectively. The images were qualita-
tively interpreted by visual inspection and quantified using
AMIDE software (free software provided by SourceForge).
Imaging acquisition in three-dimensional microcomputed
tomography of trabecular bone
The imaging of three-dimensional microcomputed tomogra-
phy for trabecular bone was collected from each
paraformaldehyde-fixed femur by using SkyScan 1076
micro-CT system (Micro Photonics Inc., Belgium). Briefly,
data were acquired at 9-μm isotropic voxel size with 360
projections by 180° scan, X-ray voltage of 50 KV, and current
of 200 μA. The duration of imaging time was 31 min per scan
and followed by 30 min of projection correction and volume
reconstruction of three-dimensional representation. Three-
dimensional render images of hind paws were generated
through original volumetric reconstructed images by CTAn
and CTVol software (Micro Photonics Inc.).
Nuclear-cytoplasmic fractionation
Mature osteoclasts (5×106) were seeded on 6 cm dish and
incubated with DV (M.O.I=5) at 37 °C in α-MEM media
(1.5 ml/6 cm dish) for 2 h. After removing unbound DV, cells
were further incubated in fresh α-MEM media (4 ml/6 cm
dish). After 12 h postinfection, cells were harvested for WB
analysis. Nuclear-cytoplasmic fractionation was performed
using the NE-PER Nuclear and Cytoplasmic Extraction
Reagents kit (Thermo Fisher Scientific) according to the man-
ufacturer’s protocol.
Detection of NFATc1 by immunoblotting
The cytoplasmic (50 μg) and nuclear extracts (15 μg) were
separated on 12 % SDS-PAGE before blotting onto PVDF
membrane. Lysates were probed with mouse anti-NFATc1
monoclonal antibody (sc-7294 Santa Cruz Biotechnology
Inc.) 1:200 in 2.5 % milk/TBST at 4 °C overnight, anti-
histone H3 (H0134 sigma) 1:1000 in 2.5 % milk/TBST at
4 °C overnight, or anti-GAPFH (MAB374, Millipore)
1:4000 in 1 % BSA/TBST at room temperature for 1 h.
Immunoblots were developed with HRP-conjugated anti-
mouse IgG antiserum (cat. no. AP181P; Chemicon) or perox-
idase affinipure goat anti-rabbit IgG (H+L) (111-035-144
Jackson Immuno) , fo l lowed by incubat ion with
SuperSignal™ West Femto Maximum Sensitivity Substrate
(34096 Thermo).
Statistical analysis
All data were presented as mean±SEM and analyzed using
GraphPad Prism software. An unpaired two-tailed Student’s t
test (for parametric data) or Mann-Whitney test (for nonpara-
metric data) was used to determine the significance between
two sets of data. When more than two groups were compared,
a one-way ANOVA with the post hoc Bonferroni test (for
parametric data) or a Kruskai-Wallis with post hoc Dunn’s test
(for nonparametric data) was used for multiple comparisons.
Results
Osteoclasts are susceptible to DV infection
To understand whether osteoclasts are susceptible to flaviviral
infection, human CD14+ monocytes and mouse bone marrow
cells (from STAT1-deficient mice) were incubated with M-
CSF and RANKL for 17 and 9 days, respectively, to differen-
tiate into osteoclasts. The success of osteoclast differentiation
was confirmed by the presence of osteoclast marker TRAP, an
alkaline phosphatase abundant in the osteoclast is able to hy-
drolyze the naphthol AS-BI phosphoric acid to couple with
fast garnet GBC and form insoluble maroon dye deposited at
sites of activity. TRAP+ giant cells were multinucleated (up-
per, Fig. 1a) and have ring-like F-actin structure by Hoechst/
phalloidin double staining (lower, Fig. 1a). Similar finding
was observed in mouse osteoclasts derived from bone marrow
(Fig. S1a, b) as that of human osteoclasts. In addition, human
osteoclasts expressed higher level of CD51/CD61 (left mid-
dle, Fig. 1b), while the expression level of CLEC5A in human
Fig. 1 Osteoclasts are susceptible to DV infection and secrete
proinflammatory cytokines via CLEC5A. a Human osteoclasts (with
multinucleated, left) and macrophages (right) with TRAP (upper,
purple red color) and phalloidin (lower, green color) staining,
respectively. Scale bar, 200 μm. b Detection of osteoclast markers
(CD51/61) and CLEC5A in human osteoclasts and macrophages by
flow cytometry (gray shadow: isotype control; mean fluorescence
intensity of each antibody staining was indicated). c Human osteoclasts
and macrophages were infected with DV, and viral antigen NS3 (red
color) was detected by immunofluorescence staining at 24 h
postinfection. Cells were countered stained with Hoechst (blue) and
phalloidin (green). Scale bar, 200 μm. d Viral titers in culture
supernatants of human osteoclasts and macrophages were determined
by plaque assay. e TNF-α secretion from DV-infected human
osteoclasts (2 × 104/well) and macrophages (2 × 104/well) were
determined by ELISA. f DV-induced secretion of TNF-α and IL-6 from
human osteoclasts were inhibited by anti-CLEC5A mAb (clone:
3E12A2, 1 μg in the 200 μl/well). Supernatants were harvested at 24 h
postinfection to determine cytokine levels by ELISA. Data were collected
and expressed as mean ± SEM from at least three independent
experiments. For f, ANOVA tests were performed and all the infections
were performed at M.O.I. = 5
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osteoclasts was similar to macrophages (lower, Fig. 1b). To
understand whether human osteoclasts were susceptible to
DV infection, cells were incubated with DV (M.O.I. =5) for
2 h, followed by washing to remove unbound virus. As shown
in Fig. 1c, DV nonstructural protein NS3 (red color) was de-
tectable in 7–10 % of osteoclasts at 24 h post-DV infection.
The STAT1-deficent mouse osteoclasts and macrophages
were also susceptible to DV infection, though the infectivity
(2–5 %) is lower than human counterparts (Fig. S1c). To fur-
ther confirm the replication of DV in human osteoclasts, we
collected the supernatants from DV-infected osteoclasts and
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time points after incubation. We found that virus titers
(Fig. 1d) and TNF-α secretion (Fig. 1e) from DV-infected
osteoclasts and macrophages were similar. Moreover, anti-
CLEC5A mAb was able to suppress the release of DV-
induced cytokines (TNF-α and IL-6) from osteoclasts
(Fig. 1f). All the observations suggest that DV not only infects
and replicates in osteoclasts but also induces proinflammatory
cytokine release from osteoclasts via CLEC5A.
Osteoclasts are susceptible to flaviviral infections
We further compared the susceptibility of human osteoclasts
and macrophages to members of flaviviruses, including DV,
Japanese encephalitis virus (JEV), and West Nile Virus
(WNV). To address this question, cells were incubated with
DV, JEV, and WNV, respectively (M.O.I. =5), and superna-
tants were harvested to determine virus titer and cytokine re-
lease at different time points postinfection. We found that the
DV titer was much higher than that of JEVand WNV, respec-
tively, in the supernatants of both macrophages and osteo-
clasts (Fig. 2a). In addition, DV induced similar amount of
TNF-α (Fig. 2b) and IL-6 (Fig. 2c) in human osteoclasts and
macrophages, while JEV and WNV were less efficient to in-
duce cytokine release from osteoclasts (left, Fig. 2b, c) than
macrophage (right, Fig. 2b, c) under the same condition (left,
Fig. 2b, c), despite JEV was as efficient as DV to induce the
Osteoclasts





























































































































































































































Fig. 2 Osteoclasts are
preferentially infected by dengue
virus. a–c Human osteoclasts
(7 × 105/well) and macrophages
(7 × 105/well) were infected with
DV, JEV, and WNV (M.O.I. = 5),
respectively, and supernatants
were harvested at indicated time
points to determine virus titer by
plaque assay (a), and supernatants
were harvested to determine the
release of TNF-α (b) and IL-6 (c)
by ELISA. d Human osteoclasts
(3 × 105/well) and macrophages
(3 × 105/well) were preincubated
with anti-CLEC5A mAb or
isotype control, followed by DV,
JEV, or WNV infection
(M.O.I. = 5). Supernatants were
harvested at 24 h postinfection to
determine cytokine levels by
ELISA. Data were collected and
expressed as mean± SEM from at
least three independent
experiments. ANOVA tests were
performed. *P< 0.05, for DV
group versus group of JEV and
WNV infection
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release of TNF-α and IL-6 from macrophages (right, Fig. 2b,
c). This observation suggests that osteoclasts are preferentially
susceptible to DV infection. In addition, antagonistic anti-
CLEC5A mAb efficiently inhibited the secretion of TNF-α
and IL-6 from human osteoclasts and macrophages (Fig. 2d).
Thus, human osteoclasts are as susceptible as macrophages,
and produce similar amounts of TNF-α and IL-6 after DV
infection. Similar findings were observed in the mouse coun-
terparts (Fig. S2). The stat1−/− osteoclasts produced higher
amount of TNF-α (left, Fig. S2a) and were more susceptible
to DV than to JEV and WNV infection (left, Fig. S2b), while
the susceptibility of stat1−/− macrophages to all the three vi-
ruses were similar (right, Fig. S2a, b). TheWTosteoclasts and
macrophages produced less cytokines (Fig. S2a) and were
more resistant to DV infection (100-fold less) than stat1−/−
osteoclasts and macrophages (Fig. S2b) under the same con-
dition. Compared to STAT1-deficient cells (stat1−/−clec5+/+),
stat1−/−clec5a−/− osteoclasts, and macrophages produced
much less cytokine (Fig. S2a). This observation further sug-
gests that DV-induced cytokine production is via CLEC5A.
DVactivates osteoclasts and upregulates osteolytic activity
via CLEC5A
It has been shown that stimulation of CLEC5A by agonistic
mAb results in augmented osteoclastogenesis in vitro [9], and
crosslinking of CLEC5A-DAP12 induces intracellular calci-
ummobilization [17]. Thus, we asked whether DVwas able to
activate transcription factor NFATc1, a master regulator of
osteoclast differentiation and activation, [18, 19] to upregulate
osteolytic activity. To address this question, human osteoclasts
were incubated with DV (M.O.I. = 5) for 24 h, followed by
immunofluorescence staining to detect nuclear translocation
of NFATc1. We found that NFATc1 located in the cytosol
(green color, Fig. 3a) without DV infection (mock control).
After DV infection, NFATc1 was translocated from cytosol to
nuclei in cells treated with isotype antibody (yellow color). In
contrast, anti-CLEC5A mAb effectively inhibited DV-
mediated NFATc1 translocation. To further confirm this ob-
servation, we detect the presence of NFATc1 in nuclear lysate
by western blot (Fig. 3b). At 12 h after infection, NFATc1 was
detected in nuclear lysates when osteoclasts were infected
with live or UV-inactivated DV, suggesting that NFATc1
translocation is independent of DV replication. Similarly,
anti-CLEC5A mAb effectively inhibited DV-mediated
NFATc1 translocation. This observation suggests that DV-
induced NFATc1 translocation is via CLEC5A and is indepen-
dent of DV replication.
We further examined the osteolytic activity of DV-infected
osteoclasts by pit formation assay [20]. To address this ques-
tion, osteoclasts (2 × 104) were incubated with DV
(M.O.I. = 5), in the presence or absence of anti-CLEC5A
mAb for 2 h, followed by removal of unbound DV. The DV-
infected osteoclasts were further incubated with bone slice in
vitro for 6 days. Bone slice were then stained with toluidine
blue to determine the resorbed area (pits) under an inverted
microscope (Fig. 3c), and the supernatants were harvested to
determine the amount of C-telopeptide of type I collagen
(CTX-1), which was released from bone slice and regarded
as the marker for bone turnover, by ELISA (Fig. 3d). The
average pit numbers on bone slice were 8±1 when incubated
with uninfected osteoclasts. In contrast, DV infection upregu-
lated osteolytic activity to increase pit numbers up to 27±2
(Fig. 3c). Moreover, anti-CLEC5A mAb efficiently sup-
pressed osteolytic activity in DV-infected osteoclasts, while
isotype control antibody has no inhibitory effect (Fig. 3c).
This observation further suggests that DV upregulates
osteolytic activity via CLEC5A.
We further measured the amount of C-telopeptide of type I
collagen (CTX-1) in the culture supernatant of osteoclasts
before and after DV infection by ELISA. As shown in
Fig. 3c, increased CTX-1 level (from 1.4 ± 0.17 to 2.59
± 1.1 ng/ml) was observed after DV infection, while anti-
CLEC5A mAb reduced CTX-1 release from bone slice
(0.39±0.24 ng/ml) (Fig. 3d). All the above observation sug-
gested that DV is able to infect osteoclasts to increase
osteolytic activity via CLEC5A.
Dynamics of bone homeostasis after DV infection in vivo
We further investigated whether DV infection caused acute
bone inflammation in vivo. Because mice are not the natural
host for DV, and wild-type mice are resistant to DV infection,
the mouse-adapted DV (NGC-N strain) was used to infect the
STAT1-deficiency mice as described previously [4] to inves-
tigate whether DValters bone homeostasis in vivo. To address
this question, STAT1-deficient mice were infected with DV
( 2 × 10 5 PFUs /mou s e ) a n d e x am i n e d b y 1 8 F -
fluorodeoxyglucose-positron emission tomography/
computed tomography (18F-FDG PET/CT) and technetium-
99m MDP single-photon emission tomography/computed to-
mography (99mTc-MDP SPECT/CT), to determine the inflam-
mation status and relevant bone reaction, respectively. During
the process of infection, activated granulocytes and lympho-
cytes had high glucose utilization; thus, regions of infection
and inflammation were imaged as foci of high 18F-FDG up-
take. It was interesting to note that increased glucose metabol-
ic activity in the sacroiliac junction (arrows) was observed at
day 3 postinfection (Fig. 4a). The glucose metabolic activity
in sacroiliac junction peaked at day 5 and subsided subse-
quently at day 7 postinfection. This observation suggests that
DVinfection caused severe inflammatory reaction in bone and
surrounding soft tissues. Furthermore, uptake of 99mTc-MDP
gradually increased in the sacroiliac junction (arrows) from
day 3 and reached peak at day 7 postinfection (Fig. 4b). This
observation indicated that the 99mTc-MDP delivered by blood
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flowwas incorporated into the osteogenic new bone formation
incited by the infection. Thus, the metabolic imaging not only
disclosed active inflammation involving the sacroiliac junc-
tion at early infection but also detected the reparative process
which occurred later than the acute inflammation. We further
detected the serum level of C-telopeptide of type I collagen
(CTX-1) released from type I collagen in bone tissue. The
basal CTX-1 serum level was 12 ng/ml before infection.
After infection, CTX-1 serum level increased from day 3,
peaked at day 5, and subsided at day 7 post-DV infection
a









































Fig. 3 DV activates osteoclasts and upregulates osteolytic activity via
CLEC5A. a Human osteoclasts (1 × 105/well) were preincubated with
anti-CLEC5A mAb or isotype control, followed by DV infection. Cells
were fixed at 24 h postinfection for immunofluorescence staining and
were examined under a confocal microscope (Olympus FV1000). Scale
bars, 10 μm. Green color: NFATc1; red color: Hoechst 33342; yellow
color: merge of NFATc1 (green) and Hoechst 33342 (red). b Human
osteoclasts (5 × 106) were preincubated with anti-CLEC5A mAb or
isotype control, followed by DV infection. Cells were harvested at 12 h
postinfection for WB analysis. c Determination of osteolytic activity by
Bpit formation^ assay.Mature human osteoclasts were seeded on the bone
slices and incubated with DV for 2 h in the presence of isotype control or
CLEC5A mAb. The resorbed areas (pits) were examined under a
microscope (Nikon) at day 6 after DV infection. Five images per each
bone slice were randomly photographed, and the resorbed areas were
counted and represented as mean ± SEM (under each picture) from three
independent experiments. d Supernatants from bone slices incubated with
human osteoclasts and DV were harvested at day 6 after DV infection to
determine C-telopeptide of type I collagen (CTX-1) level by ELISA
(CrossLaps for Culture). Data were collected and expressed as mean
± SEM ANOVA tests were performed and all the infections were
performed at M.O.I. = 5
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(Fig. 4c). The trend of CTX-1 serum level was in accord with
the 18F-FDG uptake in STAT1-deficient mice (Fig. 4a), sug-
gesting that DV induced remarkable inflammation at day 5
postinfection, followed by increased osteolytic activity and
bony destruction before reactive new bone formation (as re-
vealed by 99mTc-MDP uptake in Fig. 4b).
CLEC5A-deficient mice resist DV-induced disturbance
of bone homeostasis
To understand the role of CLEC5A in DV-induced distur-
bance of bone homeostasis in vivo, STAT1-deficient mice
(wild-type mice are resistant to DV infection) were crossed
with CLEC5A-deficient mice to produce stat1−/−clec5a−/−
double knockout mice as described previously [5]. At day 5
postinfection, DV replicated efficiently in bone marrow of
STAT1-deficient (stat1−/−clec5a+/+) mice (Fig. S3a) and up-
regulation of tnf-α (Fig. S3b) and il-6 (Fig. S3c) was also
noted in the stat1−/−clec5a+/+ mice, but not stat1−/−clec5a−/
− mice. We further compared the dynamics of bone homeo-
stasis by the three-dimensional microcomputed tomography
(Fig. 5a). As shown in Fig. 5b, DV infection caused the de-
crease of trabecular bone number (Tb-N) (black column, up-
per left) and bone volume to tissue volume (BV/TV) (black
column, lower left) at day 7 after DV infection. In contrast, the
Tb-N and BV/TV ratio were higher in CLEC5A-deficinet
mice (white column). Moreover, the separation between tra-
beculae distance (Tb-Sp) increased after DV infection, and the
Tb-Sp in CLEC5A-deficient mice is maintained in the same
level (upper right, Fig. 5b). However, the bonemineral density
did not change after DV infection in both WT littermates and
CLEC5A-deficinet mice (lower right, Fig. 5b). This observa-
tion suggests that CLEC5A regulates DV-induced disturbance
of bone homeostasis.
Anti-CLEC 5AmAb counteracts DV-induced disturbance
of bone homeostasis
We further asked whether administration of antagonistic anti-
CLEC5A mAb [4] was able to modulate bone homeostasis in
DV-infected WT mice (stat1−/−clec5a+/+). As shown in
Fig. 6a, reduction of bonemass was noted in mice treated with
isotype mAb at day 7 post-DV infection. In contrast, admin-
istration of anti-CLEC5A mAb efficiently inhibited DV-
induced reduction of bone mass (right most, Fig. 6a).
Furthermore, anti-CLEC5A mAb (while column, Fig. 6b)
was able to prevent DV-induced reduction of trabecular bone
number (upper left, Fig. 6b), BV/TVratio (lower left, Fig. 6b),
and the increase of trabeculae distance (upper right, Fig. 6b).
However, anti-CLEC5A mAb did not alter bone mineral den-
sity in mice with or without DV infection (lower right,
Fig. 6b).
Furthermore, anti-CLEC5A mAb efficiently prevented the
increase of CTX-1 serum level after DV infection (Fig. 6c).
All the above evidence suggests that DV-induced bone in-
flammation and disturbance of bone homeostasis is via
CLEC5A, and blockade of CLEC5A is able to attenuate
osteolytic activity in DV-infected mice. Thus, antagonistic
anti-CLEC5A mAb is not only able to attenuate DV-induced
lethality and neuronal inflammation [4–6] but also has the
potential to suppress DV-induced osteolytic activity to main-
tain bone homeostasis during DV infection.
Discussion
While macrophages and dendritic cells are susceptible to DV
infection, the role of osteoclasts in DV infection has not been























Fig. 4 DV infection causes bone tissue inflammation and disturbance of
bone homeostasis in STAT1-deficient mice. a Representative 18F-FDG
PET/CT imaging of the STAT1-deficient mice at days 3, 5, and 7 after DV
infection. Increased 18F-FDG uptake in the left sacroiliac junction (arrow)
was observed from day 3 postinfection and subsided at day 7. Normal
variations of tracer uptake in brown fat of the upper back region (arrow
head) and paraspinal muscles (double arrow head) and tracer
accumulation in the urinary bladder (asterisk) were noted. b 99m
Tc-MDP SPECT/CT bone scan at day 5 postinfection showed slightly
increased bony uptake of radiotracer in the upper part of left sacroiliac
junction (arrow), and more intense uptake was detected at day 7. Tracer
was accumulated in the urinary bladder (asterisk). Data from a, b were
collected from five independent experiments. c Serum of DV-infected
mice were harvested at indicated days after DV inoculation and
C-telopeptide of type I collagen (CTX-1) were determined by RatLaps
ELISA kit. Data were collected and expressed as mean± SEM. ANOVA
tests were performed
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osteoclasts and enhanced osteolytic activity via CLEC5A
(Fig. 3). Moreover, the imaging data further demonstrated that
DV caused inflammatory reactions in bone tissue (Fig. 4) and
increased osteolytic activity in vivo (Figs. 5 and 6). All these
observation suggests that DV can infect and upregulate
osteolytic activity in vivo.
One of the typical clinical symptoms of dengue patients is
the Bshattering pain,^which cannot be suppressed by the non-
steroid anti-inflammatory drug (NSAID) in dengue patients.
Thus, dengue infection is also known as Bbreakbone fever.^
However, the underlyingmechanism for the extremely painful
sensation of muscle and joints observed in dengue patients is
still unclear. It has been shown that increased osteolytic activ-
ity contributes to pain sensation in inflammatory diseases, and
the normally innocuous stimuli produce pain sensation during
the inflammatory status [21]. Moreover, the increased osteo-
clastic bone resorption are frequently associated with bone
pain, which is likely due to the acidosis environment caused
by the protons secreted from activated osteoclasts [13].
Furthermore, increased osteolytic activity does not only con-
tribute to complete Freund’s adjuvant (CFA)-induced bone
pain [13] but also contributes to the pain sensation in patients
suffered from cancer bone pain [22], rheumatoid arthritis, and
osteoporosis [23]. Therefore, it is reasonable to speculate that
DV-induced inflammatory reaction in bone tissues, as well as
the increased osteolytic activity of DV-infected osteoclasts,
may contribute the severe pain sensation in dengue patients.
Up to now, only very few human viruses (such as measles
virus and human immunodeficiency virus) have been reported













































































































Fig. 5 CLEC5A is responsible
for DV-induced dynamic change
of bone structure in vivo. a The
imaging of three-dimensional
microcomputed tomography for
trabecular bones from DV-
challenged stat1−/−clec5a+/+ and
stat1−/−clec5−/− mice
(2 × 105 PFUs per mouse) at day 7
postinfection. b Parameters for
the trabecular bone number (Tb-
N), bone volume to tissue volume
(BV/TV), separation between tra-
beculae distance (Tb-Sp), and
bonemineral density of trabecular
bone were quantitated before and
after DV infection. Data were
collected and expressed as mean
± SEM from at five independent
experiments. Two-tailed
Student’s t tests were performed
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However, there is no any report showing that virus can infect
osteoclasts and upregulates its osteolytic activity. Results from
this study clearly demonstrate that DV can infect and replicate
in osteoclasts, as well as upregulates osteolytic activity to
disturb bone homeostasis in mouse model. Thus, the painful
sensation in dengue patients may be due to the unique ability
of DV to activate osteoclasts and disturb bone homeostasis.
This argument is supported by the observation that the CTX-1
serum level is also upregulated in dengue patients (Fig. S4),
suggesting increased osteolytic activity during DV infection.
Because mice are not the natural host for DVand wild-type
mice are resistant to DV infection, even though extremely
high dose of DV (2 × 109 pfu/mouse) did cause mild
hemorrhaging at skin after intradermal injection in wild-type
mice [26]. Thus, the immunodeficient mice AG129 strain
(deficiency of type I and type II interferon receptors) [27]
and STAT1-deficiency mice [4] infected by the mouse-
adapted DV strains were commonly used to investigate the
pathogenesis of DV infection in vivo, when nonhuman pri-
mates are not available. Because interferons play critical roles
to inhibit DV infection, thus AG129 mice were highly suscep-
tible to DV infection and were developed for vaccine testing
because sustained DV replication were noted after DV inocu-
lation [28]. Similarly, STAT1 is a key regulator located at the
downstream of IFN signaling cascade; thus, STAT1-
deficiency mice is also susceptible to DV infection. Harris’s
group demonstrated that AG129 mice bear prolonged viral
loads in the serum and tissues than that in the STAT1-
deficient mice after inoculation of clinical isolation of













































































































Fig. 6 Anti-mCLEC5A mAb
prevents DV-induced bone loss. a
The imaging of three-dimensional
microcomputed tomography for
trabecular bone from DV-
challenged STAT1-deficient mice
(stat1−/−clec5a+/+) administered
with anti-CLEC5A mAb (clone:
3D2H6, 100 μg per mouse) or
isotype control at day 7
postinfection. b Parameters for
the trabecular bone number (Tb-
N), bone volume to tissue volume
(BV/TV), separation between
trabeculae distance (Tb-Sp), and
bonemineral density of trabecular
bone were quantitated before and
after DV infection. c Serum were
harvested at indicated days after
DV infection, and C-telopeptide
of type I collagen (CTX-1) were
determined by the RatLaps
ELISA kit. Data were collected
and expressed as mean ± SEM
from five independent
experiments. Two-tailed
Student’s t tests were performed
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Moreover, deficiency of IFNα/β and IFNγ receptors,
but not STAT1, reduced the numbers of activated NK
and B cells after DENV infection [29]. Therefore,
Harris’s group suggested that IFNR-dependent control
of primary DEN infection involves both STAT1-
dependent and STAT1-independent mechanisms. The
STAT1 pathway is necessary for clearing the initial viral
load, whereas the STAT1-independent pathway controls
later viral burden and prevents DEN disease in mice.
Thus, STAT1-deficient mice still preserves partial host
immunity against DV infection. In this study, we used
the mouse-adapted NGC strain to infect Stat1-deficient
mice for in vivo study as described previously [4]. Even
though the dynamic change of bone homeostasis was
observed in the STAT1-deficient mice after DV infec-
tion, this phenomenon needs to be further confirmed
in nonhuman primates or DV-infected patients in the
future.
In addition to DV, the arthritogenic alphaviruses (in-
cluding Rosa River virus (RRV) and chikungunya virus
(CHIKV)) have been shown to induce join pain and
polyarthralgias, and bone lesions in joints were found
in CHIKV-infected patients [30]. The molecular mecha-
nism is unknown until Chen et al. showed that RRV-
infected osteoblasts produce high levels of IL-6 and
RANKL, while the level of osteoprotegerin (OPG), the
decoy receptor of RANKL, was downregulated. The in-
creased RANKL/OPG ratio contributed to upregulation
of osteoclast activity and bone loss in RRV-infected
mice, while anti-IL-6 neutralizing mAb was able to
block RRV-induced bone loss [31]. In contrast to
alphaviruses, OPG is upregulated dramatically after DV
infection [32]. They further demonstrated that OPG
bound to von Willebrand factor (VWF) to prevent plate-
let interaction and regulate host immunity via neutraliz-
ing TRAIL and RANKL. Therefore, RRV and DV ap-
parently use distinct mechanism to upregulate osteoclast
activity to perturb bone homeostasis.
Our data further support the important roles of
CLEC5A in the pathogenesis of flaviviral infection.
We have shown that CLEC5A is critical in DV-
i n d u c e d h em o r r h a g i n g s h o c k a n d NAL P 3
inflammasome activation, and blockade of CLEC5A
by antagonistic anti-CLEC5A mAb inhibits DV- and
JEV-induced lethality [4–6]. This argument is support-
ed by the observation that the movement and activity
of anti-CLEC5A mAb-treated stat1−/−clec5a+/+ mice
were not hampered by DV infection, and administra-
tion of anti-CLEC5A mAb was able to prevent DV-
induced paralyzed (Supplementary data, video tape).
Thus, blockade of CLEC5A may become a novel strat-
egy to relieve the severe pain sensation of dengue pa-
tients in the future.
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